Core Viewpoint - The European Commission has approved a new indication for Sugli monoclonal antibody, expanding its treatment options for adult patients with advanced non-small cell lung cancer (NSCLC) [1] Company Summary - 基石药业-B's stock price increased by 4.61% to 5.90 HKD with a trading volume of 12.15 million HKD [1] - The approval allows Sugli to be used as a monotherapy for adult patients with unresectable stage III NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations, or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - The CEO, Dr. Yang Jianxin, highlighted that this new indication approval marks a significant milestone, providing comprehensive treatment coverage from stage III to IV NSCLC in Europe within just one year of the initial approval for metastatic NSCLC [1]
基石药业-B早盘涨逾5% 欧盟委员会已批准舒格利单抗的新适应症